Data / Form D filings / ZYMOGENETICS INC
ZYMOGENETICS INC: Form D filing
ZYMOGENETICS INC, a biotechnology company in Seattle, WA, filed a Form D with the SEC in 2008. The latest, on November 17, 2008, reports $15.5 million sold of a $15.5 million offering to 2 investors.
Find out what ZYMOGENETICS INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1201 EASTLAKE AVENUE EAST, Seattle, WA, 98102
- Phone
- (206) 442-6600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Wa
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1129425
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 17, 2008 | New notice | $15,510,000 | $15,510,000 | $0 | 2 | Nov 5, 2008 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan S. Leff | Director | |
| Heather L. Franklin | Executive Officer | |
| David H. MacCallum | Director | |
| Edward E. Penhoet, Ph.D. | Director | |
| David I. Hirsch, Ph.D. | Director | |
| Judith A. Hemberger, Ph.D. | Director | |
| Nicole Onetto, M.D. | Executive Officer | |
| Kurt Anker Nielsen | Director | |
| Bruce L.A. Carter, Ph.D. | Executive Officer, Director | |
| Lars Rebien Sorensen | Director | |
| James A. Harper | Director | |
| Darren R. Hamby | Executive Officer | |
| Douglas E. Williams, Ph.D. | Executive Officer | |
| Michael J. Dwyer | Executive Officer | |
| James A. Johnson | Executive Officer | |
| Vaughn B. Himes, Ph.D. | Executive Officer | |
| Suzanne M. Shema, J.D. | Executive Officer |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Nov 17, 2008 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ZYMOGENETICS INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.